stockrow
Saturday 7 November 2026
Export PPCB’s income statement to Excel — free account
Propanc Biopharma Inc
PPCB Healthcare Biotechnology
- EPS
- −99.6%
- Free cash flow
- −1,637.4%
- Total debt
- −21.4%
Quarter to June 2026, against a year earlier
1.79
0.15
+9.15%
Follow PPCB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (169.85%) | (138.20%) | (2,129.18%) | (1,236.83%) |
+8 more TTM periods Free account |
|
| (122.15%) | (104.68%) | (882.16%) | (702.98%) | ||
ROIC |
(125.86%) | (116.59%) | (390.17%) | (269.80%) | |
Return on Tangible Assets |
(381.25%) | (405.99%) | (1,639.23%) | (1,220.89%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(50.60) | (46.58) | (58.69) | (43.07) | |
Free Cash Flow |
(5.69) | (4.18) | (3.13) | (2.12) | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(53.18%) | (38.91%) | (27.13%) | (13.71%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(42.23) | (27.95) | (90.03) | (78.75) | |
Operating CF/Net income |
0.29 | 0.22 | 0.05 | 0.03 | |
Depreciation/Fixed assets |
0.26 | 0.17 | 0.11 | 0.13 | |
Capex/Depreciation |
(4.90) | (7.00) | (15.40) | (48.67) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(50.56) | (46.52) | (58.55) | (42.77) | |
Capex per Share |
(0.04) | (0.05) | (0.14) | (0.30) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026